Rafael (NYSE:RFL) Stock Price Down 2.3%

Rafael Holdings, Inc. (NYSE:RFL)’s share price dropped 2.3% during trading on Tuesday . The stock traded as low as $1.69 and last traded at $1.69. Approximately 18,300 shares changed hands during mid-day trading, a decline of 29% from the average daily volume of 25,741 shares. The stock had previously closed at $1.73.

Rafael Stock Down 2.3 %

The company has a market capitalization of $41.54 million, a PE ratio of 16.90 and a beta of 1.32. The stock has a 50-day moving average of $1.76 and a 200 day moving average of $1.79.

Rafael (NYSE:RFL) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($0.08) EPS for the quarter. The business had revenue of $0.07 million for the quarter. Rafael had a net margin of 776.36% and a negative return on equity of 4.31%.

Institutional Trading of Rafael

A number of institutional investors and hedge funds have recently modified their holdings of RFL. UBS Group AG grew its holdings in Rafael by 143.7% during the first quarter. UBS Group AG now owns 13,648 shares of the company’s stock valued at $35,000 after purchasing an additional 8,047 shares during the period. Charles Schwab Investment Management Inc. bought a new position in Rafael during the first quarter valued at $26,000. HRT Financial LP bought a new position in Rafael during the first quarter valued at $34,000. Osaic Holdings Inc. grew its holdings in Rafael by 178.9% during the second quarter. Osaic Holdings Inc. now owns 31,800 shares of the company’s stock valued at $66,000 after purchasing an additional 20,400 shares during the period. Finally, Atria Wealth Solutions Inc. bought a new position in Rafael during the first quarter valued at $81,000. 11.30% of the stock is owned by hedge funds and other institutional investors.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.